Press Releases Search News Category Company ReleasesCompany StatementsFinancial ReleasesProduct Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title PDF Version Nov 30, 2022 AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022 Nov 16, 2022 Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics Oct 27, 2022 ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks Oct 12, 2022 Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022 Oct 03, 2022 Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine Sep 16, 2022 Danicopan (ALXN2040) add-on to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) met primary endpoint in ALPHA Phase III trial for patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis Jun 23, 2022 ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson disease community May 05, 2022 ULTOMIRIS® (ravulizumab-cwvz) met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder Apr 28, 2022 ULTOMIRIS® (ravulizumab-cwvz) approved in the US for adults with generalized myasthenia gravis Apr 06, 2022 ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 11 - 20 of 630